Chemiluminescence Immunoassay (CLIA) Market

Executive Summary

Chemiluminescence Immunoassay (CLIA) Market was valued at US $8.76 billion in 2021 and is projected to grow at 8.47% CAGR over the forecast period to reach US $14.28 billion by 2027. Chemiluminescence Immunoassay (CLIA) Market represented US $1.32 billion opportunity over 2019-2021 and estimated to create US $5.51 billion opportunity in 2027 over 2021.

Chemiluminescence Immunoassay (CLIA) from Consainsights analyses the Chemiluminescence Immunoassay (CLIA) Market in the Life Sciences industry over the forecast period to 2027.

Chemiluminescence Immunoassay (CLIA) research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Chemiluminescence Immunoassay (CLIA) segmentation includes Product Type, Application, End User and Geography.

Based on the Product Type, the Chemiluminescence Immunoassay (CLIA) analysis covers Analyzers, Reagents, Consumables.

In Product Type segment, Analyzers segment has highest cagr growth of 7.49%.

Based on the Application, the Chemiluminescence Immunoassay (CLIA) analysis covers Oncology, Autoimmune Disorder, Infectious Disease, Cardiovascular Disease, Endocrine Disorders, Others.

In Application segment, Oncology segment has highest cagr growth of 7.49%.

Based on the End User, the Chemiluminescence Immunoassay (CLIA) analysis covers Pharmaceutical and Biotechnology Companies, Hospital and Clinical Laboratories, Others.

In End User segment, Pharmaceutical and Biotechnology Companies segment has highest cagr growth of 7.49%.

Based on the region, the Chemiluminescence Immunoassay (CLIA) analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include F. Hoffmann-La Roche AG, Mindray Medical International Limited, Siemens Healthcare GmbH, Beckman Coulter Inc. (Danaher Corporation), DiaSorin S.p.A., Sysmex Corporation, Randox Laboratories Ltd., Tosoh Corporation, Shenzhen New Industries Biomedical Engineering Co., Ltd., BioMerieux and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, Analyzers segment has the highest revenue of US $4.73 billion and is expected to grow at CAGR of 7.49% by 2027 Analyzers segment has highest cagr growth of 7.49%.

Analyzers

Analyzers segment was valued at US $4.02 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $7.71 billion by 2027. Analyzers segment represented US $0.71 billion opportunity over 2019-2021 and estimated to create US $2.98 billion opportunity in 2027 over 2021.

Reagents

Reagents segment was valued at US $2.74 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $5.25 billion by 2027. Reagents segment represented US $0.48 billion opportunity over 2019-2021 and estimated to create US $2.03 billion opportunity in 2027 over 2021.

Consumables

Consumables segment was valued at US $0.69 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $1.32 billion by 2027. Consumables segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.51 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Oncology segment has the highest revenue of US $3.50 billion and is expected to grow at CAGR of 7.49% by 2027 Oncology segment has highest cagr growth of 7.49%.

Oncology

Oncology segment was valued at US $2.98 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $5.70 billion by 2027. Oncology segment represented US $0.53 billion opportunity over 2019-2021 and estimated to create US $2.20 billion opportunity in 2027 over 2021.

Autoimmune Disorder

Autoimmune Disorder segment was valued at US $1.90 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $3.63 billion by 2027. Autoimmune Disorder segment represented US $0.33 billion opportunity over 2019-2021 and estimated to create US $1.40 billion opportunity in 2027 over 2021.

Infectious Disease

Infectious Disease segment was valued at US $1.11 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $2.12 billion by 2027. Infectious Disease segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.82 billion opportunity in 2027 over 2021.

Cardiovascular Disease

Cardiovascular Disease segment was valued at US $0.77 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $1.48 billion by 2027. Cardiovascular Disease segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.57 billion opportunity in 2027 over 2021.

Endocrine Disorders

Endocrine Disorders segment was valued at US $0.51 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $0.99 billion by 2027. Endocrine Disorders segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.38 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.19 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $0.35 billion by 2027. Others segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.14 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Pharmaceutical and Biotechnology Companies segment has the highest revenue of US $3.82 billion and is expected to grow at CAGR of 7.49% by 2027 Pharmaceutical and Biotechnology Companies segment has highest cagr growth of 7.49%.

Pharmaceutical and Biotechnology Companies

Pharmaceutical and Biotechnology Companies segment was valued at US $3.24 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $6.22 billion by 2027. Pharmaceutical and Biotechnology Companies segment represented US $0.57 billion opportunity over 2019-2021 and estimated to create US $2.40 billion opportunity in 2027 over 2021.

Hospital and Clinical Laboratories

Hospital and Clinical Laboratories segment was valued at US $2.94 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $5.64 billion by 2027. Hospital and Clinical Laboratories segment represented US $0.52 billion opportunity over 2019-2021 and estimated to create US $2.18 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $1.26 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $2.42 billion by 2027. Others segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.93 billion opportunity in 2027 over 2021.